WHO approves trials for two new Ebola vaccines
Summary
The World Health Organization approved trials of two vaccines designed for the Bundibugyo strain of Ebola, amid an outbreak in the Democratic Republic of the Congo. The WHO expects trial results in early 2027; meanwhile, a British health worker infected in the DRC is being evacuated to the United Kingdom for treatment.Key Facts
- The Bundibugyo outbreak has caused more than 5,300 deaths since May, according to the article.
- Africa CDC reported 10,444 confirmed Bundibugyo cases in the DRC, describing it as the fastest-growing outbreak in the country’s history.
- A trial that began last month is testing Ervebo, a vaccine approved for the Zaire strain but not designed specifically for Bundibugyo.
- The two newly approved trials will test vaccines designed specifically for the Bundibugyo strain.
- The DRC’s National Institute for Biomedical Research is leading the trial, with support from the WHO and other partners.
- The article reports nine cases, including two deaths, in Kenya and one confirmed case in Nigeria.
- The WHO is supporting DRC’s neighboring countries as they prepare for possible cross-border spread.
- A British healthcare worker infected in the DRC is in stable condition and is expected to arrive in the UK by Thursday for specialist treatment; the UK government said the risk to the public is low.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
